Track record · closed signal

Stoke Therapeutics, Inc. (STOK) — closed signal from October 3, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on January 1, 2026.

Predicted vs. what happened

STOK price · publication thesis → realized outcomesplit-adjusted
$24.85 Published $31.81 Target $31.74 Window close $38.69 Peak
$24.20 – $25.00Entry zone — fair-value band
$24.85Published — price the day we called it
$31.81Target — the price the thesis aimed for
$38.69Peak — highest point inside the window, not a realized return
$31.74Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 5 days.

Peak price
$38.69
peak on October 16, 2025 — not a realized return
Peak gain
+55.7%
peak, from the publication price
Window close
$31.74
end-of-window price, context only
Days to target
5
Window
October 3, 2025 – January 1, 2026

The thesis — published October 3, 2025

Predicted growth
+28%
over the measurement window
Target price
$31.81
the price the thesis aimed for
Entry zone
$24.20 – $25.00
the fair-value band we waited for
Price at publication
$24.85
published October 3, 2025
Confidence
88%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Stoke appears to be riding very upbeat investor mood. Its price has been steady and improving after a brief pause, and many biotech peers are hitting new yearly highs. Fresh pipeline news across the group is making investors more willing to take risk. With optimism very high and solid basics for a company still in trials, small pullbacks may be good entries over the next 3 months. Key risks: trial timing and normal biotech swings.

Primary drivers

  • Steady upward price trend with strong recent momentum in trading activity
  • Very positive investor mood, plus helpful news lifting the biotech group
  • Multiple drug programs give several paths for success if results are good
  • Recent biotech updates are making investors more willing to take measured risks

How it played out

STOK: target reached in 5 days

Lyra published STOK at $24.85 on 2025-10-03 with a short-term thesis for 28% growth. The thesis pointed to a steady upward price trend, strong recent trading activity, very positive investor mood, helpful biotech news, and several drug programs that could matter if results were good.

Inside the window, STOK reached the $31.81 target in 5 days. It later peaked at $38.69 on 2025-10-16, a 55.7% gain. By 2026-01-01, it ended at $31.74. The thesis played out. It reached the target quickly and stayed close to it at the end.

What happened during the window

On 2025-12-16, Investor's Business Daily reported that Stoke had released third-quarter results on 2025-11-04, with revenue up 117% to $10.6 million and a loss of $0.65 per share.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All STOK signals